Bryan Hartzler, PhD

In nearly two decades at UW, Dr. Hartzler’s work has principally focused on the dissemination and implementation of empirically-supported health services for persons with substance use disorders. His scientific and services efforts to date includes local, regional, national, and international collaborations, encompassing federally-funded work with diverse community-based settings (i.e., addiction care, mental health, primary and specialty medical care, criminal justice, HIV care, schools), including those affiliated with the NIDA Clinical Trials Network.  In 2017, Dr. Hartzler was awarded a five-year SAMHSA grant to direct the Northwest Addiction Technology Transfer Center (Northwest ATTC), one of 10 regional centers in the national ATTC network. The Northwest ATTC supports the addiction workforce in Alaska, Idaho, Oregon, and Washington via provision of universal, targeted and intensive technical assistance for regional treatment and healthcare organizations and their personnel.  In professional endeavors that span a science-to-service continuum, Dr. Hartzler seeks to promote adoption and implementation of useful treatment and recovery practices in community settings where they may benefit persons with substance use disorders.


Interdisciplinary Postdoctoral Fellowship, VA Puget Sound Healthcare System-Seattle, Center of Excellence in Substance Abuse Treatment and Education
Predoctoral Clinical Psychology Residency, VA Puget Sound Healthcare System-Seattle
PhD, Clinical Psychology, University of Texas at Austin
BS, Psychology, University of Washington

Department Affiliations

Recent Publications

Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19.
(2022 Jan)
J Subst Abuse Treat 132(): 108648
Rosales R, Janssen T, Yermash J, Yap KR, Ball EL, Hartzler B, Garner BR, Becker SJ

Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): A cluster-randomized type 3 hybrid effectiveness-implementation trial.
(2021 Oct 12)
Addict Sci Clin Pract 16(1): 61
Becker SJ, Murphy CM, Hartzler B, Rash CJ, Janssen T, Roosa M, Madden LM, Garner BR

Impacts of the COVID-19 pandemic on healthcare access among patients receiving medication for opioid use disorder.
(2021 Apr 1)
Drug Alcohol Depend 221(): 108617
Jacka BP, Janssen T, Garner BR, Yermash J, Yap KR, Ball EL, Hartzler B, Becker SJ

Is necessity also the mother of implementation? COVID-19 and the implementation of evidence-based treatments for opioid use disorders.
(2021 Mar)
J Subst Abuse Treat 122(): 108210
Becker SJ, Garner BR, Hartzler BJ

Use of Telehealth in Substance Use Disorder Services During and After COVID-19: Online Survey Study.
(2021 Feb 8)
JMIR Ment Health 8(2): e25835
Molfenter T, Roget N, Chaple M, Behlman S, Cody O, Hartzler B, Johnson E, Nichols M, Stilen P, Becker S

Show complete publication list »
Edit Profile